SCHEMBL1677347

SCHEMBL1677347

CCOC(=O)c1nc(-c2ccco2)cs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
ALDH1A1 P00352 11/20 0.55
HSD17B10 Q99714 6/20 0.55
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
ALOX15 P16050 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
PKM P14618 2/20 0.51
POLB P06746 5/20 0.50
ADORA2B P29275 2/20 0.50
MAPT P10636 4/20 0.48
KDM4E B2RXH2 6/20 0.47
HPGD P15428 5/20 0.47
TSHR P16473 3/20 0.47
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694852 0.79 ALDH1A1 (0.56) L3MBTL1ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL3065254 0.78 MAPT (0.57) L3MBTL1ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL9823323 0.77 RAB9A (0.56) L3MBTL1ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL3206574 0.77 MAPT (0.60) L3MBTL1ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5761572 0.77 ALDH1A1 (0.55) L3MBTL1ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2705788 0.76 KDM4E (0.56) L3MBTL1ALDH1A1MEN1KMT2ATDP1
SCHEMBL5733736 0.76 CDC7 (0.53) ALDH1A1HSD17B10MEN1KMT2AMAPT
SCHEMBL22619882 0.76 KDM4E (0.53) L3MBTL1ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL28928759 0.75 ESR1 (0.49) L3MBTL1ALDH1A1MEN1KMT2ATDP1
SCHEMBL9219906 0.75 L3MBTL1 (0.55) L3MBTL1ALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-20100280023-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2010-11-04 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
EP-1894930-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 L3MBTL1 1732/4885ALDH1A1 638/4885HSD17B10 125/4885
US-20100280023-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, GPR6 L3MBTL1 3328/4885ALDH1A1 1449/4885HSD17B10 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.